Eiffel to focus on developing inhaled and transdermal insulin

Eiffel Technologies (ASX : EIF) announced today it has completed further animal studies in its development of improved injectable insulin, and would focus resources on collaborations with pharmaceutical companies working on inhaled or transdermal insulin.

The studies confirmed that Eiffels re-engineered insulin is at least equivalent to the commercially available forms of the drug.

Eiffel has supplied re-engineered insulin to companies for use in either oral or transdermal delivery. These companies will be testing Eiffel's product in different delivery devices.

“We must prioritise our insulin research to areas where the technology has the potential to add maximal commercial and shareholder value“, said Eiffel’s Managing Director and CEO, Christine Cussen. “The potential opportunities for inhaled and oral insulin are large and we want to capitalise on these opportunities.”